Open Access

Recombinant human lactoferrin enhances the efficacy of triple therapy in mice infected with Helicobacter pylori

  • Authors:
    • Yuping Yuan
    • Qinyi Wu
    • Guoxiang Cheng
    • Xuefang Liu
    • Siguo Liu
    • Juan Luo
    • Aimin Zhang
    • Li Bian
    • Jianquan Chen
    • Jiajun Lv
    • Xiangqian Dong
    • Gang Yang
    • Yunzhen Zhu
    • Lanqing Ma
  • View Affiliations

  • Published online on: June 17, 2015     https://doi.org/10.3892/ijmm.2015.2251
  • Pages: 363-368
  • Copyright: © Yuan et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Helicobacter pylori (H. pylori) is a life-threatening pathogen which causes chronic gastritis, gastric ulcers and even stomach cancer. Treatment normally involves bacterial eradication; however, this type of treatment only has a rate of effectiveness of <80%. Thus, it is a matter of some urgency to develop new therapeutic strategies. Lactoferrin, a member of the transferrin family of iron‑binding proteins, has been proven to be effective in removing a vast range of pathogens, including H. pylori. In the present study, we examined the effectiveness of recombinant human lactoferrin (rhLf) isolated from transgenic goats as a treatment for H. pylori in vitro and in vivo. For the in vivo experiments, BALB/c mice received an intragastric administration of 0.1 ml of a suspension of H. pylori. The mice were then divided into 4 groups: group A, treated with saline; group B, treated with 1.5 g of rhLF; group C, treated with the standard triple therapy regimen; and group D, treated with the standard triple therapy regimen plus.5 g of rhLF. Following sacrifice, the stomach tissues of the mice were histologically examined for the presence of bacteria. For the in vitro experiments, the bacteria were cultured in BHI broth and RT-qPCR and western blot analysis were carried out to determine the mRNA and protein levels of virulence factors (CagA and VacA) in the cultures. Our results revealed that rhLf not only inhibited the growth of H. pylori, but also suppressed the expression of two major virulence factors. Moreover, rhLf markedly increased bacterial eradication and effectively reduced the inflammatory response when combined with the standard triple therapy regimen. These results provide evidence supporting the use of rhLF as an adjuvant to traditional therapeutic strategies in the treatment of H. pylori.
View Figures
View References

Related Articles

Journal Cover

August-2015
Volume 36 Issue 2

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yuan Y, Wu Q, Cheng G, Liu X, Liu S, Luo J, Zhang A, Bian L, Chen J, Lv J, Lv J, et al: Recombinant human lactoferrin enhances the efficacy of triple therapy in mice infected with Helicobacter pylori. Int J Mol Med 36: 363-368, 2015.
APA
Yuan, Y., Wu, Q., Cheng, G., Liu, X., Liu, S., Luo, J. ... Ma, L. (2015). Recombinant human lactoferrin enhances the efficacy of triple therapy in mice infected with Helicobacter pylori. International Journal of Molecular Medicine, 36, 363-368. https://doi.org/10.3892/ijmm.2015.2251
MLA
Yuan, Y., Wu, Q., Cheng, G., Liu, X., Liu, S., Luo, J., Zhang, A., Bian, L., Chen, J., Lv, J., Dong, X., Yang, G., Zhu, Y., Ma, L."Recombinant human lactoferrin enhances the efficacy of triple therapy in mice infected with Helicobacter pylori". International Journal of Molecular Medicine 36.2 (2015): 363-368.
Chicago
Yuan, Y., Wu, Q., Cheng, G., Liu, X., Liu, S., Luo, J., Zhang, A., Bian, L., Chen, J., Lv, J., Dong, X., Yang, G., Zhu, Y., Ma, L."Recombinant human lactoferrin enhances the efficacy of triple therapy in mice infected with Helicobacter pylori". International Journal of Molecular Medicine 36, no. 2 (2015): 363-368. https://doi.org/10.3892/ijmm.2015.2251